Submit Manuscript    >>    Login | Register

New Options for Complete Risk Reduction in Atrial Fibrillation Patients


Atrial Fibrillation (AF) is a growing public health problem expected to affect up to 15 million patients by 2050 [1].  While AF can be highly symptomatic, the risks associated with the arrhythmia determine long-term outcome. AF increases mortality 1.5 fold in men and 1.9 fold in women and confers an approximate 4% yearly risk for stroke and systemic embolism [2-3].  Many new therapies and strategies for comprehensive AF risk management are being developed.  Many of these offer the potential for greater stroke risk reduction with fewer bleeding complications.

Credits: George Thomas, MD; Bruce B Lerman, MD



Biosense Webster
event date
Introduction to AFib
Ablation Specialist

View Ablation Specialists